Psychotic Depression Treatment in Lower Merion Township, PA

This Is One of the Most Misunderstood and Undertreated Conditions in Psychiatry. You Deserve Better Than That.

Psychotic depression does not look like what most people imagine when they hear the word psychosis. There are usually no dramatic breaks from reality, no scenes from a movie. What there is, often, is a profound and crushing depression layered with beliefs that feel absolutely real but are not, that you have committed a terrible wrong, that you are fundamentally worthless, that something catastrophic is happening or about to happen. There may be voices. There may be persistent, intrusive images that your mind generates without your permission. And underneath all of it is one of the most severe forms of depression that exists.

People living with psychotic depression are often ashamed. They hide the psychotic symptoms because they feel too strange or too frightening to say out loud. They are sometimes misdiagnosed, their depression treated without the psychotic features ever being addressed. And because the condition requires a more complex treatment approach than standard depression, they often cycle through medications without reaching adequate relief.

At Ketamine Wellness Infusions PA, located minutes from Lower Merion Township in Bala Cynwyd, we offer IV ketamine infusions as part of a comprehensive treatment approach for people living with psychotic depression, including cases that have not responded adequately to antidepressants and antipsychotics. Our founder Jill Gabay is a senior CRNA with more than 30 years of anesthesia experience, a member of the American Society of Ketamine Physicians, Psychotherapists and Practitioners, and personally present for every infusion we administer.

We take complex cases seriously. Schedule a consultation and let us talk about what is actually possible for you.

What Psychotic Depression Is and Why It Is So Difficult to Treat

Psychotic depression, formally known as major depressive disorder with psychotic features, is a severe form of depression that includes at least one psychotic symptom, typically delusions, hallucinations, or both. The psychotic content in this condition is almost always mood-congruent, meaning it reflects and amplifies the depressive themes. Delusions typically involve guilt, punishment, worthlessness, illness, or failure. Hallucinations, when present, often involve voices reinforcing the same themes.

It affects roughly one in four people hospitalized for depression, making it far more common than most people realize. Yet despite its prevalence and severity, research published in PMC found that only about 5% of people with psychotic depression receive the combination of an antidepressant and an antipsychotic that clinical guidelines consider the pharmacological standard of care.

The treatment challenge is significant. Neither antidepressants alone nor antipsychotics alone are typically sufficient. The American Psychiatric Association practice guidelines recommend with their highest level of confidence that psychotic depression be treated with the combination of an antidepressant and an antipsychotic, or with electroconvulsive therapy. ECT has documented efficacy for this condition, with response rates of 80 to 90% in controlled trial settings. But ECT is not available everywhere, carries its own side effect profile including temporary memory disruption, and real-world remission rates in community settings have been documented at 30 to 47%, substantially lower than clinical trial figures.

For people who have not achieved adequate relief through medication combinations, or who cannot access ECT, IV ketamine represents a meaningful additional option with a growing evidence base and a fundamentally different mechanism of action.

How IV Ketamine Fits Into Treatment for Psychotic Depression

It is important to be clinically precise here. Ketamine is not a standalone replacement for antipsychotic medication in psychotic depression. People living with this condition typically need antipsychotic coverage, and that clinical management belongs with a prescribing psychiatrist as part of a broader treatment plan.

What IV ketamine offers is a powerful, rapid-acting intervention for the depressive component of psychotic depression, the dimension that antipsychotics alone address incompletely and that antidepressants may take weeks or months to meaningfully improve, if they improve it at all.

Ketamine targets the glutamate system through NMDA receptor antagonism rather than the serotonin or dopamine pathways that standard antidepressants and antipsychotics address. By blocking NMDA receptors, ketamine triggers a cascade that promotes synaptogenesis, the rapid growth of new synaptic connections, and stimulates the release of brain-derived neurotrophic factor in the prefrontal cortex and hippocampus. These are the brain regions that severe depression, including psychotic depression, consistently damages over time. The result is antidepressant relief that arrives in hours rather than weeks.

Research published in PMC on glutamate receptor antagonists and depression notes that GSK-3 inhibition, one of ketamine's downstream effects, reduces both depressive and psychotic symptoms simultaneously, suggesting that ketamine's mechanism may address psychotic features through a pathway that neither conventional antidepressants nor antipsychotics fully engage. A 2024 secondary analysis of the ELEKT-D trial published in the American Journal of Psychiatry found greater symptom improvement in patients treated with IV ketamine compared with ECT in a depressed population, though the researchers appropriately noted the limited observation period.

For complex, treatment-resistant presentations of psychotic depression where medications have not provided adequate relief, IV ketamine used in coordination with a prescribing psychiatrist offers a clinically grounded, evidence-based adjunct that can accelerate and deepen the response.

What Responsible Treatment Looks Like at Our Clinic

People with psychotic depression require careful, experienced clinical oversight. This is not a condition where one approach fits all, and it is not a condition where clinical shortcuts are acceptable.

Before any infusion takes place, Jill Gabay conducts a thorough consultation reviewing your full psychiatric and medical history, your current medications including any antipsychotics and mood stabilizers, your previous treatment responses, and your current symptom picture. We work in coordination with your prescribing psychiatrist, not around them. If IV ketamine is not appropriate for your situation, we will say so clearly.

If you move forward, the standard initial course is six IV ketamine infusions completed over approximately two to three weeks. Each infusion lasts 40 to 60 minutes and takes place in a calm, monitored environment with blankets, eye masks, and essential oil diffusers. Jill or a member of our care team is present throughout every session monitoring your vital signs. You are not alone in that room.

The transient dissociative effects some patients experience during infusion are managed within the session and resolve promptly afterward. For patients with psychotic depression specifically, the carefully controlled clinical environment and continuous supervision we provide are not optional features. They are the standard of care.

After your series, Jill conducts personal follow-up check-ins to assess your response and coordinate with your broader treatment team on next steps. Complex presentations require ongoing communication, and we take that responsibility seriously.

Why Clinical Expertise Matters Most for Complex Cases

Psychotic depression is not the condition to bring to a clinic with limited experience in psychiatric-level dosing. It requires a clinician who understands not just how to administer ketamine, but how to assess complex presentations, how to manage the infusion experience for a patient with an active psychotic component, and how to work collaboratively within a broader psychiatric care framework.

Jill Gabay has more than 30 years of anesthesia experience. She is a member of the American Society of Ketamine Physicians, Psychotherapists and Practitioners. Fellow ketamine clinicians have specifically praised her expertise in psychiatric-level dosing. That expertise is not incidental. For a condition as serious as psychotic depression, it is exactly what the situation calls for.

Her physician supervisor Dr. Rubin brings more than 20 years of clinical experience as a board-certified oncologist and serves as a Clinical Associate Professor of Medicine at Drexel University College of Medicine. The physician oversight at this clinic reflects the clinical complexity of the patients we serve.

Our clinic at 146 Montgomery Ave, Suite 202 in Bala Cynwyd sits directly inside Lower Merion Township, accessible from Ardmore, Wynnewood, Narberth, Penn Valley, Bryn Mawr, and throughout the Main Line. You do not need to travel into Philadelphia for this level of clinical depth.

Frequently Asked Questions About Psychotic Depression Treatment in Lower Merion Township